For US residents only.

How Treatment May Help

ZYKADIA® (ceritinib)

Select to see clinical trial results for ZYKADIA when used as the first treatment (Starting with ZYKADIA) or when used as the second treatment (Switching to ZYKADIA).

Select to see clinical trial results for ZYKADIA when used as the first treatment (Starting with ZYKADIA) or when used as the second treatment (Switching to ZYKADIA).

Select to see clinical trial results for ZYKADIA when used as the first treatment (Starting with ZYKADIA) or when used as the second treatment (Switching to ZYKADIA).

Consider a powerful therapy for your type of cancer

ZYKADIA® (ceritinib) vs chemotherapy was studied in patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who had never received any targeted treatment or chemotherapy. In this study, 189 patients took ZYKADIA and 187 patients received chemotherapy.

This study measured progression-free survival (PFS). This is the time from when the patient is first assigned to receive a treatment until the day that a computed tomography scan confirms that the cancer is growing again or the patient dies (even if the death is not due to cancer).

Results in the overall study population 

ZYKADIA doubled the amount of time patients lived without their tumors spreading or growing vs chemotherapy.

 

  • For patients taking ZYKADIA, the median PFS was 16.6 months. This means that half of the patients went longer than 16.6 months and half went less than 16.6 months
  • For patients treated with chemotherapy, the median PFS was 8.1 months

bar chart showing that the time before tumors started getting worse was 16.6 months with ZYKADIA versus 8.1 months with chemotherapy

 

Additional information studied

ZYKADIA has not been shown to increase how long patients lived compared with patients who received chemotherapy.

7 out of 10 patients had an antitumor response with ZYKADIA vs nearly 3 out of 10 with chemotherapy

This means that in many patients treated with ZYKADIA, tumors shrank or disappeared.

Changes in the size or number of tumors are measured by the overall response rate. This number includes patients whose tumors became smaller or fewer in number (which is called a partial response), and patients whose tumors disappeared completely (which is called a complete response). In this study, 72% of patients taking ZYKADIA had a partial response and 1% had a complete response. Among the patients receiving chemotherapy, 27% had a partial response and none had a complete response. Complete response is not the same as a cure.

 

Additional information studied

Duration of response for ZYKADIA vs chemotherapy

Duration of response is a measure of how long a treatment can keep tumors from growing again after a response has first been detected. This is different from PFS, which measures time until tumor growth in everybody who was assigned to treatment—whether or not they responded.

Patients treated with ZYKADIA had a longer median length of response: 23.9 months vs 11.1 months with chemotherapy.

 

bar chart showing that, in patients who responded to treatment, the time before tumors started growing again was 23.9 months with ZYKADIA versus 11.1 months with chemotherapy
  • In the 137 patients taking ZYKADIA who had a tumor response, the median duration of response was 23.9 months
  • In the 50 patients who had a response while receiving chemotherapy, the median duration of response was 11.1 months

ZYKADIA may help when taken as a second-line treatment

ZYKADIA® (ceritinib) has been shown to shrink or slow the growth of tumors in patients who had already taken another anaplastic lymphoma kinase (ALK) inhibitor.

ZYKADIA was studied in a clinical trial in 163 patients with ALK+ metastatic non-small cell lung cancer (NSCLC) who had previously taken crizotinib. They had stopped taking it because their NSCLC had worsened or they could not tolerate it.

The results of the study showed:

 

In more than half of the patients, ZYKADIA reduced the amount or spread of the cancer or reduced the size of the tumors.

  • 1.2% of the patients had a complete response (no detectable tumors, which is not the same as being cured)
  • 53.4% of the patients had a partial response (tumors became smaller, but could still be detected)

 

Response to treatment lasted 7.4 months.

  • This is the median time or midpoint, which means that half the patients went longer and half the patients went shorter